We unpack the FDA 510(k) summary for Bunkerhill Contrast CAC, an AI tool cleared to opportunistically detect and quantify coronary artery calcium on routine contrast-enhanced chest CTs. We discuss the shift from non-contrast to contrast imaging, the pivotal performance data, and what it means for clinical workflows.

Key points

  • Cleared for adults aged 30 years and above to detect and estimate the quantity of coronary artery calcification.
  • Specifically designed to analyze non-gated, contrast-enhanced chest CT images, unlike its predicate device which uses non-contrast scans.
  • Outputs an estimated volume score in mm3 rather than traditional Agatston units.
  • Pivotal testing demonstrated a sensitivity of 0.957 and specificity of 0.929.
  • A 50-case bridging study comparing contrast to non-contrast images showed a mean bias of -4.36 mm3.
  • The software is intended as adjunctive information only and does not replace the physician's evaluation or the original patient report.

Source: FDA 510(k) summary K260166: Bunkerhill Contrast CAC (BunkerHill Health) - U.S. Food and Drug Administration, 2026

This episode is an AI-generated conversation summarising a public document; the hosts' voices are synthetic. It is for information only and is not medical advice. Always refer to the original source.

Full transcript: https://ai-in-medicine-podcast.vercel.app/episodes/company-spotlight-bunkerhill-contrast-cac-opportunistic-screening-on-r-dfb2f3

Podden och tillhörande omslagsbild på den här sidan tillhör Mike Rawson. Innehållet i podden är skapat av Mike Rawson och inte av, eller tillsammans med, Poddtoppen.